Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.
Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.
复制标题
DOI:
10.1016/j.ejca.2014.06.023
复制
发表时间:
2014-10
影响因子:
8.4
通讯作者:
Metzger, Monika L.
中科院分区:
文献类型:
--
作者:
Bhojwani, Deepa;Darbandi, Rashid;Pei, Deqing;Ramsey, Laura B.;Chemaitilly, Wassim;Sandlund, John T.;Cheng, Cheng;Pui, Ching-Hon;Relling, Mary V.;Jeha, Sima;Metzger, Monika L.
Asparaginase and steroids can cause hypertriglyceridemia in children with acute lymphoblastic leukemia (ALL). There are no guidelines for screening or management of patients with severe hypertriglyceridemia (>1000 mg/dL) during ALL therapy. Fasting lipid profiles were obtained prospectively at 4 time-points for 257 children consecutively enrolled on a frontline ALL study. Risk factors were evaluated by the exact chi-square test. Details of adverse events and management of hypertriglyceridemia were extracted retrospectively. Eighteen of 257 (7%) patients developed severe hypertriglyceridemia. Older age and treatment with higher doses of asparaginase and steroids on the standard/high-risk arm were significant risk factors. Severe hypertriglyceridemia was not associated with pancreatitis after adjustment for age and treatment arm or with osteonecrosis after adjustment for age. However, patients with severe hypertriglyceridemia had a 2.5 to 3 times higher risk of thrombosis compared to patients without, albeit the difference was not statistical significant. Of the 30 episodes of severe hypertriglyceridemia in 18 patients, 7 were managed conservatively while the others with pharmacotherapy. Seventeen of 18 patients continued to receive asparaginase and steroids. Triglyceride levels normalized after completion of ALL therapy in all 12 patients with available measurements. Asparaginase- and steroid-induced transient hypertriglyceridemia can be adequately managed with dietary modifications and close monitoring without altering chemotherapy. Patients with severe hypertriglyceridemia were not at increased risk of adverse events, with a possible exception of thrombosis. The benefit of pharmacotherapy in decreasing symptoms and potential complications requires further investigation.
登录
查看更多内容
影响因子:
20.3
作者:
Oudin, Claire;Simeoni, Marie-Claude;Michel, Gerard
通讯作者:
Michel, Gerard
影响因子:
20.3
作者:
Kawedia, Jitesh D.;Kaste, Sue C.;Relling, Mary V.
通讯作者:
Relling, Mary V.
影响因子:
5.3
作者:
Rosenson, RS;Shott, S;Tangney, CC
通讯作者:
Tangney, CC
DOI:
10.1056/nejmoa0900386
发表时间:
2009-06-25
期刊:
The New England journal of medicine
影响因子:
--
作者:
Pui CH;Campana D;Pei D;Bowman WP;Sandlund JT;Kaste SC;Ribeiro RC;Rubnitz JE;Raimondi SC;Onciu M;Coustan-Smith E;Kun LE;Jeha S;Cheng C;Howard SC;Simmons V;Bayles A;Metzger ML;Boyett JM;Leung W;Handgretinger R;Downing JR;Evans WE;Relling MV
通讯作者:
Relling MV
影响因子:
5.5
作者:
Kabata, T;Kubo, T;Tomita, K
通讯作者:
Tomita, K